18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
2016-12-20
FDA-2016-D-0620
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Applicants must submit information on chemistry, manufacturing, and controls (CMC) to support the approval of new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) or the conditional approval of applications for conditional approval (CNADAs). The Center for Veterinary Medicine (CVM) reviews the CMC information for new animal drugs to ensure that applicants have methods and controls in place for manufacturing, processing, and packaging that are adequate for assuring and preserving the identity, strength, quality, and purity of the new animal drug and, in the case of a generic drug, to ensure that it is equivalent to the reference listed new animal drug (RLNAD). In order to improve the process for submission and review of CMC information for animal drugs, CVM has developed a series of questions that focus on the critical scientific and regulatory issues and pharmaceutical attributes essential for ensuring the quality of new animal drug substances and products. Termed Question-based Review (QbR), these questions provide a general framework for original CMC submissions to investigational new animal drug (INAD) files, generic investigational new animal drug (JINAD) files, NADAs, ANADAs, CNADAs, and veterinary master files (VMFs).
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2016-D-0620.
Pharma CMC2024-10-15
摩熵医药(原药融云)2024-08-21
数屿医械2024-06-24
数屿医械2024-06-13
数屿医械2024-05-30
摩熵医药(原药融云)2024-05-27
药事纵横2024-02-28
药通社2023-12-26
摩熵医药(原药融云)2023-12-13
药通社2023-06-25
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-30
2024-10-29
2024-10-28
2024-10-24
2024-10-24
2024-10-23
2024-10-23
2024-10-22
2024-10-21
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15